Early referral for 24-h esophageal pH monitoring may prevent unnecessary treatment with acid-reducing medications
- First Online:
- 210 Downloads
Gastroesophageal reflux disease (GERD) affects nearly 25 % of adults; however, an objective diagnosis is rarely established. We hypothesized that patients’ symptoms and response to acid-reducing therapy are poor predictors of the outcome of 24-h esophageal pH monitoring.
A review of 24-h esophageal pH monitoring studies performed at an ambulatory tertiary care center between 2004 and 2011 was performed. Demographics, type of GERD symptoms, and duration and response to acid-reducing medications before referral for pH monitoring were collected. DeMeester score, symptom sensitivity index (SSI), and symptom index (SI) were tabulated and compared with the patients’ symptoms and response to medical therapy.
One hundred patients were included. Of all reported symptoms, only heartburn was more common in patients with positive DeMeester scores, but there were no correlations between any symptoms and SSI or SI scores. Sixty-nine percent of patients with esophageal symptoms had a positive DeMeester score compared with only 29 % of patients with extraesophageal symptoms (P < 0.01). Esophageal symptoms and endoscopic evidence of GERD significantly increased the likelihood of having a positive DeMeester score, but they had no influence on SSI or SI scores. There was no correlation between response to acid-reducing medications and DeMeester, SSI, or SI scores. A total of 536 person-years of acid-reducing medications were prescribed to the study population, of which 151 (28 %) were prescribed to patients who had a negative pH study.
Extraesophageal symptoms and response to empiric trials of acid-reducing medications are poor predictors of the presence of GERD and the DeMeester score is more likely to identify GERD in patients who met other empiric diagnostic criteria than SSI or SI. Early referral for 24-h esophageal pH monitoring may avoid lengthy periods of unnecessary medical therapy.
KeywordsGERD Esophageal pH monitoring Reflux Proton-pump inhibitors
- 4.Zhao Y, Encinosa W (2006) Gastroesophageal reflux disease (GERD) hospitalizations in 1998 and 2005: statistical brief #44. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs, RockvilleGoogle Scholar
- 7.Mujica VR, Rao SS (1999) Recognizing atypical manifestations of GERD. Asthma, chest pain, and otolaryngologic disorders may be due to reflux. Postgrad Med 105:53–55, 60, 63–56Google Scholar
- 17.Kahrilas PJ, Shaheen NJ, Vaezi MF (2008) American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 135:1392–1413, 1413 e1391–1395Google Scholar
- 44.Tseng D, Rizvi AZ, Fennerty MB, Jobe BA, Diggs BS, Sheppard BC, Gross SC, Swanstrom LL, White NB, Aye RW, Hunter JG (2005) Forty-eight-hour pH monitoring increases sensitivity in detecting abnormal esophageal acid exposure. J Gastrointest Surg 9:1043–1051 discussion 1051–1042PubMedCrossRefGoogle Scholar
- 46.Ayazi S, Hagen JA, Zehetner J, Banki F, Augustin F, Ayazi A, DeMeester SR, Oh DS, Sohn HJ, Lipham JC, DeMeester TR (2011) Day-to-day discrepancy in Bravo pH monitoring is related to the degree of deterioration of the lower esophageal sphincter and severity of reflux disease. Surg Endosc 25:2219–2223PubMedCrossRefGoogle Scholar